PCRX

• 2026-04-30 share offering or dilution eventrecentOpen filing ↗
  “…10,891 9,002 Other accrued operating expenses 10,576 12,864 Compensation and benefits 25,812 37,841 Accrued interest 2,308 782…”
  +1 more passage from the same document

  • “…782 Product returns and wholesaler service fees 11,014 11,554 Total $ 84,957 $ 95,601 NOTE 9— DEBT The carrying value of the…”
• 2026-04-30 capital return (buybacks/dividends)recentOpen filing ↗
  “…Other Comprehensive Income Balance at December 31, 2024 $ 190 $ 153 $ 343 Net unrealized loss on investments, net of tax…”
  +1 more passage from the same document

  • “…investments, net of tax (1) ( 86 ) — ( 86 ) Foreign currency translation adjustments — 1,094 1,094 Balance at March 31, 2025 $ 104 $…”
• 2026-04-30 merger or acquisition eventrecentOpen filing ↗
  “…solely in its capacity as representative for the former securityholders of MyoScience and certain other defendants, seeking…”
  +1 more passage from the same document

  • “…merger agreement for the MyoScience Acquisition (the “MyoScience Merger Agreement”), specifically related to the achievement of…”
• 2026-02-26 share offering or dilution eventrecentOpen filing ↗
  “…and Indebtedness Servicing our indebtedness requires a significant amount of cash, and we may not have sufficient cash flow from…”
  +1 more passage from the same document

  • “…our 2025 Notes. The partial repurchase of the 2025 Notes was completed with our net proceeds from the issuance of the 2029 Notes. For…”
• 2026-02-26 capital return (buybacks/dividends)recentOpen filing ↗
  “…of our assets as well as prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments.…”
  +1 more passage from the same document

  • “…in debt covenants), regulatory restrictions and alternative uses of capital. There can be no assurance that repurchases will be…”
• 2026-02-26 regulatory investigationrecentOpen filing ↗
  “…postsurgical local analgesia that was approved by the FDA in March 2021 and the indications for adductor canal block and sciatic…”
• 2026-02-26 Department of Justice inquiryrecentOpen filing ↗
  “…that was approved by the FDA in March 2021 and the indications for adductor canal block and sciatic nerve block in the popliteal…”
  +1 more passage from the same document

  • “…a subpoena from the U.S. Department of Justice, U.S. Attorney’s Office for the District of New Jersey, requiring the production of a…”
• 2026-02-26 merger or acquisition eventrecentOpen filing ↗
  “…utilizing GQ Bio’s HCAd gene therapy vector platform and assets with disease-modifying potential in prevalent musculoskeletal…”
  +1 more passage from the same document

  • “…platform and assets with disease-modifying potential in prevalent musculoskeletal diseases. For more information, see Note 4, GQ…”

Recorded SEC filings in plain language — not advice or a prediction.